Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Total Lisata Therapeutics, Inc. Stockholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Common stock, beginning balance (in shares) at Dec. 31, 2021			3,986,000
Beginning balance at Dec. 31, 2021	$ 92,000	$ 92,254	$ 4	$ 546,044	$ (70)	$ (453,016)	$ (708)	$ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(10,852)	(10,852)				(10,852)
Share-based compensation (in shares)			48,000
Stock issued (shares)			4,000
Share-based compensation	960	960		960
Net proceeds from issuances of common stock	29	29		29
Foreign currency translation adjustment	0
Common stock, ending balance (in shares) at Jun. 30, 2022			4,038,000
Ending balance at Jun. 30, 2022	82,137	82,391	$ 4	547,033	(70)	(463,868)	(708)	(254)
Common stock, beginning balance (in shares) at Mar. 31, 2022			4,035,000
Beginning balance at Mar. 31, 2022	88,241	88,495	$ 4	546,637	(196)	(457,242)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(6,626)	(6,626)				(6,626)
Share-based compensation (in shares)			(1,000)
Stock issued (shares)			4,000
Share-based compensation	367	367		367
Net proceeds from issuances of common stock		29		29
Foreign currency translation adjustment	0
Unrealized gain on marketable securities	126	126			126
Common stock, ending balance (in shares) at Jun. 30, 2022			4,038,000
Ending balance at Jun. 30, 2022	$ 82,137	82,391	$ 4	547,033	(70)	(463,868)	(708)	(254)
Common stock, beginning balance (in shares) at Dec. 31, 2022	7,866,061		7,867,000
Beginning balance at Dec. 31, 2022	$ 66,324	66,578	$ 8	574,548	(29)	(507,241)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from option exercises (in shares)	1,227,776
Common stock, ending balance (in shares) at Mar. 31, 2023			7,999,000
Ending balance at Mar. 31, 2023	$ 60,703	60,957	$ 8	575,137	(52)	(513,428)	(708)	(254)
Common stock, beginning balance (in shares) at Dec. 31, 2022	7,866,061		7,867,000
Beginning balance at Dec. 31, 2022	$ 66,324	66,578	$ 8	574,548	(29)	(507,241)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(10,214)	(10,214)				(10,214)
Share-based compensation (in shares)			107,000
Stock issued (shares)			76,000
Share-based compensation	1,173	1,173		1,173
Net proceeds from issuances of common stock	297	297		297
Proceeds from option exercises	$ 155	155		155
Proceeds from option exercises (in shares)	82,500		83,000
Foreign currency translation adjustment	$ (22)				(22)
Unrealized gain on marketable securities	$ 1	1			1
Common stock, ending balance (in shares) at Jun. 30, 2023	8,132,357		8,133,000
Ending balance at Jun. 30, 2023	$ 57,714	57,968	$ 8	576,173	(50)	(517,455)	(708)	(254)
Common stock, beginning balance (in shares) at Mar. 31, 2023			7,999,000
Beginning balance at Mar. 31, 2023	60,703	60,957	$ 8	575,137	(52)	(513,428)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,027)	(4,027)				(4,027)
Share-based compensation (in shares)			(25,000)
Stock issued (shares)			76,000
Share-based compensation	584	584		584
Net proceeds from issuances of common stock	297	297		297
Proceeds from option exercises	155	155		155
Proceeds from option exercises (in shares)			83,000
Foreign currency translation adjustment	(10)	(10)			(10)
Unrealized gain on marketable securities	$ 12	12			12
Common stock, ending balance (in shares) at Jun. 30, 2023	8,132,357		8,133,000
Ending balance at Jun. 30, 2023	$ 57,714	$ 57,968	$ 8	$ 576,173	$ (50)	$ (517,455)	$ (708)	$ (254)